Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi
Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )
10 Jul 2025

Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results

Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results ( Prof Stefano Luminari - University of Modena and Reggio Emilia, Modena, Italy )
9 Jul 2025

Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia

Dr Anthony Stein - City of Hope, Duarte, USA
Bexmarilimab plus azacitidine shows promising response in relapsed/refractory myelodysplasia ( Dr Anthony Stein - City of Hope, Duarte, USA )
27 Jun 2025

Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM

Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France
Subcutaneous isatuximab via on-body delivery system matches IV efficacy with better experience in RRMM ( Prof Xavier Leleu - Poitiers University Hospital, Poitiers, France )
27 Jun 2025

Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies

Dr Moritz Fürstenau - University of Cologne, Cologne, Germany
Triple combination of venetoclax-ibrutinib-obinutuzumab prolongs PFS compared to venetoclax-CD20-antibodies ( Dr Moritz Fürstenau - University of Cologne, Cologne, Germany )
27 Jun 2025

The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL

Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA
The combination of acimtamig and AlloNK therapy demonstrates promising efficacy in R/R cHL ( Dr Amitkumar Mehta - University of Alabama at Birmingham, Birmingham, USA )
27 Jun 2025

Key insights from lung cancer research at ASCO 2025

Dr Luis Raez - Memorial Cancer Institute, Miami, USA
Key insights from lung cancer research at ASCO 2025 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )
27 Jun 2025

POLA-R-GEMOX regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma

Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA
POLA-R-GEMOX  regimen is a promising option for relapsed/refractory diffuse large B-cell lymphoma ( Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA )
27 Jun 2025

ASCO 2025: Importance of early testing in metastatic prostate cancer

Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano
ASCO 2025: Importance of early testing in metastatic prostate cancer ( Prof Eleni Efstathiou, Dr Elena Castro, Prof Gerhardt Attard and Dr Brigida Maiorano )
3 Jun 2025

Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases

Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA
Encorafenib/binimetinib/nivolumab combo improves PFS in BRAF-mutant melanoma brain metastases ( Dr Zeynep Eroglu - Moffitt Cancer Center, Tampa, USA )
3 Jun 2025

Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma

Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA
Enhanced pathologic response with neoadjuvant pembrolizumab plus vidutolimod in high-risk resectable melanoma ( Dr Ahmad Tarhini - Moffitt Cancer Center, Tampa, USA )
3 Jun 2025

Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer

Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy
Sacituzumab govitecan shows efficacy signals in muscle-invasive urothelial bladder cancer ( Dr Brigida Maiorano - IRCCS San Raffaele Hospital, Milan, Italy )
3 Jun 2025